Fred Alger Management, LLC Intellia Therapeutics, Inc. Transaction History

Fred Alger Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$58.27 - $118.99 $2.32 Million - $4.75 Million	-39,889 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$100.76 - $138.36 $575,339 - $790,035	5,710 Added 16.71%	39,889 $4.72 Million
Q3 2021 Nov 15, 2021	BUY	$132.37 - $176.78 $1.87 Million - $2.5 Million	14,164 Added 70.77%	34,179 $4.59 Million
Q2 2021 Aug 16, 2021	SELL	$60.88 - $161.91 $52,235 - $138,918	-858 Reduced 4.11%	20,015 $3.24 Million
Q1 2021 May 17, 2021	BUY	$46.59 - $83.68 $393,545 - $706,844	8,447 Added 67.98%	20,873 $1.68 Million
Q4 2020 Feb 16, 2021	BUY	$18.83 - $63.53 $233,981 - $789,423	12,426 New	12,426 $676,000

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.02B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fred Alger Management, LLC with notifications on news.